Status:
COMPLETED
Bevacizumab and Long Acting Gas in Diabetic Vitrectomy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Proliferative Diabetic Retinopathy
Eligibility:
All Genders
20-85 years
Phase:
PHASE3
Brief Summary
Persistent or recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy complications is a common occurrence with an incidence of 12% to 63%. This complication may prolong vitreous clear...
Detailed Description
From December 2006 to August 2007, consecutive patients undergoing primary pars plana vitrectomy for active proliferative diabetic retinopathy were recruited for the prospective study. Included cases ...
Eligibility Criteria
Inclusion
- anticoagulant therapy has not been used prior to surgery or during post-operative follow-up period.
- no medical history of blood diseases associated with abnormal blood coagulation is present.
- Having active fibrovascular proliferation with vitreo-retinal adhesions in 3 or more sites but not extending beyond the equator in more than one quadrant.
- Severe retinopathy with anticipation of silicone oil usag
- Age is between 20 to 85 years old.
Exclusion
- Not primary pars plana vitrectomy
- post-operative follow-up duration less than three months
- Pregnancy
- HbA1c \> 8.0
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00656435
Start Date
December 1 2006
End Date
February 1 2008
Last Update
April 11 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, National Taiwan University Hospital
Taipei, Taiwan, 100